These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 20399451

  • 21. Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.
    Beebe-Dimmer JL, Cetin K, Shahinian V, Morgenstern H, Yee C, Schwartz KL, Acquavella J.
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):70-8. PubMed ID: 22114014
    [Abstract] [Full Text] [Related]

  • 22. Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment.
    Graham-Steed TR, Soulos PR, Dearing N, Concato J, Tinetti ME, Gross CP.
    J Geriatr Oncol; 2014 Oct 01; 5(4):343-51. PubMed ID: 25240918
    [Abstract] [Full Text] [Related]

  • 23. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
    Siris ES, Baim S, Nattiv A.
    Postgrad Med; 2010 Jan 01; 122(1):82-90. PubMed ID: 20107292
    [Abstract] [Full Text] [Related]

  • 24. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.
    Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A, National Osteoporosis Guideline Group.
    Osteoporos Int; 2008 Oct 01; 19(10):1395-408. PubMed ID: 18751937
    [Abstract] [Full Text] [Related]

  • 25. The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice.
    Watts NB.
    J Womens Health (Larchmt); 2011 Apr 01; 20(4):525-31. PubMed ID: 21438699
    [Abstract] [Full Text] [Related]

  • 26. [Androgen deprivation therapy for prostate cancer and osteoporotic risk].
    Cortet B, Lartigau E, Caty A, Moulinier F, Staerman F, Villamizar-Vesga J, Villers A.
    Prog Urol; 2012 Sep 01; 22 Suppl 2():S31-8. PubMed ID: 23098788
    [Abstract] [Full Text] [Related]

  • 27. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
    Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL.
    J Clin Oncol; 2005 Nov 01; 23(31):7897-903. PubMed ID: 16258089
    [Abstract] [Full Text] [Related]

  • 28. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.
    Briot K, Paccou J, Beuzeboc P, Bonneterre J, Bouvard B, Confavreux CB, Cormier C, Cortet B, Hannoun-Lévi JM, Hennequin C, Javier RM, Lespessailles E, Mayeur D, Mongiat Artus P, Vieillard MH, Debiais F.
    Joint Bone Spine; 2019 Jan 01; 86(1):21-28. PubMed ID: 30287350
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer.
    Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M.
    J Urol; 2001 Nov 01; 166(5):1724-8. PubMed ID: 11586210
    [Abstract] [Full Text] [Related]

  • 33. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
    Khriguian J, Tsui JMG, Vaughan R, Kucharczyk MJ, Nabid A, Bettahar R, Vincent L, Martin AG, Jolicoeur M, Yassa M, Barkati M, Igidbashian L, Bahoric B, Archambault R, Villeneuve H, Mohiuddin M, Niazi T.
    J Urol; 2021 Jun 01; 205(6):1648-1654. PubMed ID: 33577365
    [Abstract] [Full Text] [Related]

  • 34. Fracture risk in patients with prostate cancer on androgen deprivation therapy.
    López AM, Pena MA, Hernández R, Val F, Martín B, Riancho JA.
    Osteoporos Int; 2005 Jun 01; 16(6):707-11. PubMed ID: 15714259
    [Abstract] [Full Text] [Related]

  • 35. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS.
    J Urol; 2007 Oct 01; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
    Higano CS.
    Nat Clin Pract Urol; 2008 Jan 01; 5(1):24-34. PubMed ID: 18185511
    [Abstract] [Full Text] [Related]

  • 38. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS.
    J Urol; 2010 Oct 01; 184(4):1316-21. PubMed ID: 20723926
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR.
    Oncology (Williston Park); 2004 May 01; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.